Explore more publications!

Press Releases

Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Chef Andreas Debuts Andreas Prime Steaks & Seafood in Uptown Dallas, Reuniting His Culinary Team from The Palm
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
GBSA connects Pangyo’s innovative companies with global media outlets through the 2025 Pangyo Global Media Meet-Up
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance -  Publication of Circular for Combined Annual General Meeting of  September 30, 2025
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
Combined General Meeting of June 11, 2025
Public Health Action Network Is A Partnering Organization for the  'Healthy Indoor Air' Event at the UN General Assembly
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
Deputy President Shipokosa Paulus Mashatile: Heritage Day 2025

Deputy President Shipokosa Paulus Mashatile: Heritage Day 2025

Statement on the Cabinet meeting of Wednesday, 17 September 2025

Statement on the Cabinet meeting of Wednesday, 17 September 2025

Combined General Meeting of June 13, 2025
WHO Cautions Chikungunya Spread Threatens Billions

WHO Cautions Chikungunya Spread Threatens Billions

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
EU Balance of Payments and International Investment Position statistical sources and methods - B.o.p. and i.i.p. e-book

EU Balance of Payments and International Investment Position statistical sources and methods - B.o.p. and i.i.p. e-book

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions